Mitsubishi UFJ Trust & Banking Corp Trims Stock Position in Hologic, Inc. (NASDAQ:HOLX)

Mitsubishi UFJ Trust & Banking Corp lessened its holdings in Hologic, Inc. (NASDAQ:HOLX) by 33.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 194,088 shares of the medical equipment provider’s stock after selling 99,302 shares during the period. Mitsubishi UFJ Trust & Banking Corp’s holdings in Hologic were worth $13,992,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently bought and sold shares of the stock. General Partner Inc. acquired a new position in shares of Hologic in the 4th quarter worth approximately $26,000. Groupama Asset Managment lifted its stake in Hologic by 9.9% during the third quarter. Groupama Asset Managment now owns 33,177 shares of the medical equipment provider’s stock worth $27,000 after purchasing an additional 2,999 shares in the last quarter. Venturi Wealth Management LLC boosted its position in shares of Hologic by 156.3% during the fourth quarter. Venturi Wealth Management LLC now owns 428 shares of the medical equipment provider’s stock worth $31,000 after buying an additional 261 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Hologic by 79.8% in the fourth quarter. EverSource Wealth Advisors LLC now owns 586 shares of the medical equipment provider’s stock valued at $42,000 after buying an additional 260 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its holdings in shares of Hologic by 36.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after buying an additional 159 shares during the period. Institutional investors and hedge funds own 94.73% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on HOLX. Royal Bank of Canada reduced their target price on shares of Hologic from $88.00 to $85.00 and set a “sector perform” rating on the stock in a report on Thursday, February 6th. Wolfe Research began coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Citigroup cut their target price on shares of Hologic from $80.00 to $70.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Stephens reiterated an “overweight” rating and issued a $84.00 price target on shares of Hologic in a research note on Thursday, February 6th. Finally, Jefferies Financial Group started coverage on shares of Hologic in a report on Tuesday, December 10th. They issued a “hold” rating and a $85.00 price objective on the stock. Eleven investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Price Performance

HOLX stock opened at $61.32 on Friday. The company has a current ratio of 3.49, a quick ratio of 2.78 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $13.76 billion, a P/E ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97. The business has a 50 day simple moving average of $65.24 and a 200-day simple moving average of $73.35. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a net margin of 18.42% and a return on equity of 19.72%. As a group, equities analysts anticipate that Hologic, Inc. will post 4.28 EPS for the current year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.